Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies. The company operates an integrated model that spans early discovery through late-stage development and commercial production, enabling it to move candidates from laboratory to market using internal capabilities as well as strategic collaborations.
Key marketed products and development programs address ophthalmology, immunology, oncology and infectious disease. Regeneron’s marketed medicines include EYLEA (aflibercept) for retinal disorders and Dupixent (dupilumab), developed and co-commercialized in partnership with Sanofi, for certain inflammatory conditions. The company has also developed antibody-based therapies for oncology and infectious disease, including combination antibody treatments for COVID‑19 during the pandemic response.
Regeneron serves patients in the United States and internationally through its own commercial operations and partner arrangements. Leadership includes founder and chief executive Leonard S. Schleifer and co‑founder and chief scientific officer George D. Yancopoulos, who have guided the company’s scientific strategy and commercial expansion. Regeneron continues to invest in platform technologies and a diversified pipeline aimed at advancing novel biologic therapies.